Boston Scientific Corp (BSX)
Debt-to-equity ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 19,282,000 | 18,886,000 | 18,226,000 | 17,850,000 | 17,573,000 | 17,640,000 | 17,251,000 | 16,735,000 | 16,623,000 | 16,461,000 | 15,942,000 | 15,720,000 | 15,327,000 | 15,564,000 | 15,616,000 | 13,804,000 | 13,877,000 | 9,698,000 | 9,424,000 | 9,232,000 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $19,282,000K
= 0.00
The debt-to-equity ratio of Boston Scientific Corp. has been relatively stable over the past eight quarters, ranging from 0.47 to 0.56. This ratio indicates the proportion of the company's capital that is financed through debt compared to equity. A lower ratio suggests that the company relies more on equity financing, which may indicate a lower level of financial risk.
Boston Scientific Corp.'s debt-to-equity ratios in the last four quarters of 2023 were consistent, hovering around 0.47 to 0.50, indicating a balanced mix of debt and equity in its capital structure. However, compared to the same quarters in 2022, there was a slight improvement in debt management, as the ratios were lower in 2023.
The increase in the debt-to-equity ratio from Q1 2022 to Q1 2023, peaking at 0.56, indicates a higher level of debt relative to equity. This could imply increased financial leverage, which may introduce additional risk. However, it is noteworthy that the ratio trended downwards in subsequent quarters, suggesting an effort to reduce debt levels.
Overall, Boston Scientific Corp.'s consistent debt-to-equity ratios indicate a stable capital structure with a moderate reliance on debt financing. The company's ability to maintain a reasonable balance between debt and equity contributes to a healthy financial position, but continued monitoring of debt levels and overall leverage is advisable to mitigate potential risks.
Peer comparison
Dec 31, 2023